Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...

Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...

In trading on Tuesday, shares of Axsome Therapeutics Inc (Symbol: AXSM) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $107 per share. By ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

The latest price target for Axsome Therapeutics (NASDAQ:AXSM) was reported by Mizuho on March 27, 2025. The analyst firm set a price target for $216.00 expecting AXSM to rise to within 12 months ...